TargetGene Biotechnologies

Genome Editing for Living Organisms

Startup

TargetGene Biotechnologies is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2012. Genome Editing for Living Organisms. The company has raised a total of $9.2M across 2 funding rounds, currently at the B stage. TargetGene Biotechnologies was founded by Yoel Shiboleth and Dan Weinthal. Key investors include Undisclosed Investor(s), Monsanto. The company has 1-10 employees. Core technologies: Biologicals, Genes.

With $9.2M in total funding, TargetGene Biotechnologies is a B-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.

$9.2M
Raised
2
Rounds
2
Investors
2
Team
2012
Founded
1
Patents
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiologicalsGenes
At a Glance
Investors
Founders
In the News

4 articles covered by sources including crisprmedicinenews.com, en.globes.co.il, www.wsj.com, www.genomeweb.com.

crisprmedicinenews.com · Dec 11, 2019
Interview: Move over CRISPR: a new platform, TGEE, could soon replace everybody's favorite gene editing tool. Interview: Yoel Shiboleth, CEO TargetGene - CRISPR Medicine
Read article ↗
Frequently Asked Questions
What does TargetGene Biotechnologies do?

TargetGene Biotechnologies is an innovative and agile biotechnology company in its development stage and poised for expansion. The companys R&D is centered around creating efficient and extremely specific DNA editing solutions in living organisms. Through its patented and patent-pending TGEE (genome editing engine) platform, TargetGene has developed RNA-guided gene targeting. The company aims to implement the TGEE platform for human gene therapy with a focus on inherited diseases and cell-based immunotherapy.

How much funding has TargetGene Biotechnologies raised?

TargetGene Biotechnologies has raised $9.2M in total funding across 2 rounds. The company is currently at the B stage. Key investors include Undisclosed Investor(s), Monsanto.

Who founded TargetGene Biotechnologies?

TargetGene Biotechnologies was founded in 2012 by Yoel Shiboleth (Co-founder & CEO), Dan Weinthal (Co-founder & COO).

What sector is TargetGene Biotechnologies in?

TargetGene Biotechnologies operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology.

Where is TargetGene Biotechnologies located?

TargetGene Biotechnologies is based in Prof. Hillel ve-Khanan Oppenheimer St 10, Rehovot, Israel, Center District.

View Full Profile Classic View Website ↗